

POSTGRADUATE LEUKEMIA CONFERENCE

# LEUKEMIA 2018

ROME (ITALY), MAY 24-25, 2018

CME CREDITS XX

Scientific Coordinator

Angelo Michele Carella

Scientific Board

Sergio Amadori, Emanuele Angelucci, Robin Foà,  
Giuseppe Saglio, Alessandro M. Vannucchi



ACC  MED

ACCADEMIA NAZIONALE DI MEDICINA

SECTION OF HEMATOLOGY

# Presentation



Leukemia is at the crossroads of hematology and oncology. It encompasses such a heterogeneous spectrum of disease entities that it is hard to preserve a unity. There is surely a greater difference between an indolent chronic lymphocytic leukemia and an acute leukemia, whether lymphoid or myeloid or mixed, than between acute lymphoblastic leukemia and most high grade non-Hodgkin's lymphomas. Yet, these malignancies composed of circulating cells, involving the bone marrow and encroaching on some of the most fundamental functions of the living organism, internal respiration, immunity and hemostasis, are of special interest to hematologists and oncologists. They also pose an enormous problem: the cure of leukemia. This is certainly one of the most exciting challenges for modern scientific medicine.

Fascinating modern technologies have opened entirely new avenues of investigation. Quite frequently, new findings in leukemic disorders have also elucidated important processes of normal physiology; this is particularly so in the lymphoproliferative diseases. However, there has been up to now a certain divergence between basic science in leukemia (derangement of the genome, growth factors, oncogenes, viruses) and therapy, which has been, and still is, mainly eradicated, with chemotherapy and bone marrow transplantation, allogeneic and autologous, in the foreground.

We seem to be approaching an era in which both trends will implement each other, allowing greater insight in to the basic processes and, at the same time, more integrated targeted and efficient therapies.

With this goal in mind, the program of this Conference is centered on a highly qualified international and Italian faculty to allow a broad and interactive exchange of experiences and opinions, as well as to share the most exciting advances between speakers and participants.

## Addressed to

Physicians specialized in Hematology and Oncology

# Preliminary program



## Thursday, May 24

- 13.00 • **Welcome and introduction**  
A.M. Carella
- **MYELODYSPLASTIC SYNDROMES**  
Chairmen: E. Angelucci
- 13.15 • **WHO classification**  
P. Musto
- 13.30 • **Somatic mutations in the novo MDS and prognosis**  
W.K. Hofmann
- 13.45 • **Therapy for lower risk patients**  
R. Latagliata
- 14.00 • **Therapy for higher risk patients**  
V. Santini
- 14.15 • **Novel agents**  
P. Fenauux
- 14.45 • **Timing of allografting**  
M.G. Della Porta
- 15.00 • **General discussion**
- 15.30 • **Concluding remarks**  
W.K. Hofmann
- 15.45 • *Coffee break*
- 16.15 • **JOHN GOLDMAN LECTURE**  
Presenter: A.M. Carella  
Speaker: J.L. Steegmann
- **CHRONIC MYELOID LEUKEMIA**  
Chairman: G. Saglio
- 16.45 • **First line therapy: still imatinib in all cases?**  
J.F. Apperley
- 17.00 • **Second line therapy: new options?**  
F. Castagnetti
- 17.15 • **ELN 2017 recommendations: what are the new goals in CML treatment?**  
A. Hochhaus
- 17.30 • **Treatment discontinuation: time for clinical practice?**  
F.X. Mahon
- 17.45 • **TKIs: comorbidities and side effects**  
M. Breccia
- 18.00 • **Can we afford a continuous TKI therapy for a life-long period?**  
E. Abruzzese
- 18.15 • **Future biological and clinical perspectives**  
M. Mauro
- 18.45 • **General discussion**
- 19.00 • **Concluding remarks**  
G. Saglio
- 19.15 • **End of the session**



## Friday, May 25

- **Ph-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS**  
Chairman: A.M. Vannucchi
- 8.30 • **Role of driver mutations in pathogenesis**  
W. Vainchenker
- 8.45 • **Clinical significance of mutations**  
M. Cazzola
- 9.00 • **Does early treatment of MF make sense?**  
F. Passamonti
- 9.15 • **Novel treatment approaches beyond JAK2 inhibitors**  
J.J. Kiladjian
- 9.30 • **Allografting in myelofibrosis**  
W. Arcese
- 9.45 • **General discussion**
- 10.15 • **Concluding remarks**  
J.J. Kiladjian
- 10.30 • *Coffee break*
- **NEW DRUGS AND DEW DATA WITH OLD DRUGS**  
Chairman: R.M. Lemoli
- 11.00 • **Update of Blinatumomab and Inotuzumab Ozogamicin in ALL**  
F. Ferrara
- 11.15 • **Target antigens and adoptive immunotherapy in AML**  
A. Isidori
- 11.30 • **FLT3 inhibitors**  
S. Sica
- 11.45 • **Venetoclax**  
F. Pane
- 12.00 • **BCR/BCL2 pathways inhibitors in CLL**  
P.P. Ghia
- 12.15 • **Obinutuzumab in lymphomas and CLL**  
U. Vitolo
- 12.30 • **Immune check-point inhibitors: from lymphomas to new perspectives**  
G. Martinelli
- 12.45 • **General discussion**
- 13.00 • *Lunch*
- **ACUTE MYELOID LEUKEMIA**  
Chairman: S. Amadori
- 14.00 • **Mutations of clinical relevance**  
B. Falini
- 14.15 • **Beyond standard induction chemotherapy: new approaches for frontline therapy**  
N. Russell



14.30 • **MRD monitoring: clinical applications and pitfalls**  
F. Buccisano

14.45 • **New concepts in the management of older patients**  
G.J. Ossenkoppele

15.00 • **Allografting: who, when, how**  
F. Ciceri

15.15 • **New agents in clinical trials**  
A. Ganser

15.30 • **General discussion**

16.00 • **Concluding remarks**  
N. Russell

• **ACUTE LYMPHOBLASTIC LEUKEMIA**

Chairman: R. Foà

16.15 • **MRD-driven management of Ph-negative ALL**  
A. Rambaldi

16.30 • **Where are we going in the management of Ph-positive ALL?**  
O.G. Ottmann

16.45 • **New genetic-based strategies**  
S. Chiaretti

17.00 • **What will be the role of MoAb?**  
P. Rousselot


17.15 • **Ex vivo growth of primary ALL and drug response profiling**  
J.P. Bourquin

17.30 • **Allografting: when and how?**  
J.M. Ribera

17.45 • **General discussion**

18.15 • **Concluding remarks**  
O.G. Ottmann

18.30 • **End of the Conference**



## Scientific Coordinator

---

### **Angelo Michele Carella**

Past-Director

Division of Hematology and BMT Unit

Ospedale Policlinico San Martino

IRCCS per l'Oncologia

Genoa

## Scientific Board

---

### **Sergio Amadori**

Institute of Hematology

Tor Vergata University Hospital

Rome

### **Emanuele Angelucci**

Division of Hematology

and BMT Unit

Ospedale Policlinico San Martino

IRCCS per l'Oncologia

Genoa

### **Robin Foà**

Institute of Hematology

Sapienza University of Rome

### **Giuseppe Saglio**

Division of Hematology

Mauriziano Hospital

University of Turin

### **Alessandro M. Vannucchi**

CRIMM-Center of Research and

Innovation of Myeloproliferative  
Neoplasms

A.O.U. Careggi

University of Florence



## Speakers and Discussant

---

**Elisabetta Abruzzese**

Rome

**Jane F. Apperley**

London (UK)

**William Arcese**

Rome

**Jean-Pierre Bourquin**

Zurich (CH)

**Massimo Breccia**

Rome

**Francesco Buccisano**

Rome

**Fausto Castagnetti**

Bologna

**Mario Cazzola**

Pavia

**Sabina Chiaretti**

Rome

**Fabio Ciceri**

Milan

**Matteo G. Della Porta**

Rozzano, MI

**Brunangelo Falini**

Perugia

**Piere Fenaux**

Paris (F)

**Felicetto Ferrara**

Naples

**Arnold Ganser**

Hannover (D)

**Paolo P. Ghia**

Milan

**Andreas Hochhaus**

Jena (D)

**Wolf-Karsten Hofmann**

Mannheim (D)

**Alessandro Isidori**

Pesaro

**Jean-Jacques Kiladjian**


Paris (F)

**Roberto Latagliata**

Rome

**Roberto M. Lemoli**

Genoa



**François-Xavier Mahon**  
Bordeaux (F)

**Giovanni Martinelli**  
Bologna

**Michael Mauro**  
New York (USA)

**Pellegrino Musto**  
Rionero in Vulture, PZ

**Oliver G. Ottmann**  
Cardiff (UK)

**Gert J. Ossenkopppele**  
Amsterdam (NL)

**Fabrizio Pane**  
Naples

**Francesco Passamonti**  
Varese

**Alessandro Rambaldi**  
Bergamo

**Josep Maria Ribera**  
Barcelona (E)

**Philippe Rousselot**  
Le Chesnay (F)

**Nigel Russell**  
Nottingham (UK)

**Valeria Santini**  
Florence

**Simona Sica**  
Rome

**Juan Luis Steegmann**  
Madrid (E)

**William Vainchenker**  
Villejuif (F)

**Umberto Vitolo**  
Turin





## CME

---

Based on Italian regulations, Accademia Nazionale di Medicina (provider n.31) will assign **XXX CME** credits to the activity (31-XXXXXX).

The meeting is addressed to physicians specialized in Hematology and Oncology.

It will not be possible to give credits to physicians specialized in different fields.

The credit certification is subject to:

- attendance at 90% of the Meeting
- the completion of the meeting evaluation form
- the completion of the final questionnaire (at least 75% of correct answer).

We would like to remind to participants that only 1/3 of the CME Credits acquired during the years 2017-2019 can come from a sponsorship.

## Official Language

---

The meeting will be held in Italian and English.

Simultaneous translation will be not provided.

## Registration

---

The participation to the Meeting is free and is addressed to a limited number of participants.

To register, please send **by May 14, 2018**:


- registration form duly filled out
- privacy statement and consent regarding personal information (back of the form)

to Accademia Nazionale di Medicina - Via M. Piaggio 17/6 - 16122 Genova  
fax. 010 83794260

e-mail: [segreteriacorsi@accmed.org](mailto:segreteriacorsi@accmed.org)

It's also possible to register on the website [www.accmed.org](http://www.accmed.org)

The registration will be confirmed by e-mail, please indicate your e-mail address on the registration form.



## Venue

---

### **The Duke Hotel**

Via Archimede, 69  
Rome

## How to reach the Venue

---

*The Duke Hotel is located in the Villa Borghese area about 1.2 km from the Historical Centre of Rome, just 20 minutes walking from Piazzale Flaminio or 5 minutes with our complimentary shuttle bus.*

*by plane:*

From the airport take the train to Termini Station, then underground A to Flaminio or the bus N. 910 to Piazza Euclide which is just 5 minutes walking to the Hotel.

*by train:*

- underground A to Flaminio or the bus N. 910 to Piazza Euclide which is just 5 minutes walking to the Hotel.
- from Piazzale Flaminio or Flaminio Underground station the Hotel is reachable in our complimentary shuttle bus service, in train Line Roma - Viterbo ( only one stop) or bus N. 492.
- from piazza Euclide it is only 5 minutes walking to the hotel.

## Promoted by

---

### **ACCADEMIA NAZIONALE DI MEDICINA**



[www.accmed.org](http://www.accmed.org)

General Manager: Stefania Ledda



## Information and Registration

---

Tel 010 83794225

Fax 010 83794260

segreteria@accmed.org

<https://leukemia.accmed.org>

## Organizing Partner

---

### **Forum Service**

Via Martin Piaggio 17/6  
16122 Genova

